E
Exscientia
AI-Driven Drug Discovery
Oxford, UK (US: Miami, Boston)
500+
About Exscientia
Industry:
TechBio
Founded:
2012
Founders:
Andrew Hopkins
Status:
Public (NASDAQ: EXAI)
Funding & Growth
Total Raised:
$600M+
Valuation:
$2B+ market cap
Stage:
Public
Key Investors:
SoftBank
Bristol Myers Squibb
Evotec
✓ Pros
- • AI-first drug discovery pioneer
- • Multiple pharma partnerships
- • Growing US presence
- • First AI-designed drug in trials
- • Strong scientific publications
✗ Cons
- • UK headquarters
- • Smaller US team
- • Stock volatility
- • Clinical-stage risk